GMAB has been the topic of a number of other research reports. Royal Bank of Canada initiated coverage on Genmab A/S in a research report on Monday, August 12th. They set an outperform rating and a $23.00 price objective on the stock. Bank of America upgraded Genmab A/S from a neutral rating to a buy rating in a report on Friday, September 13th. HC Wainwright reaffirmed a buy rating and issued a $25.00 target price on shares of Genmab A/S in a research note on Wednesday, November 20th. JPMorgan Chase & Co. upgraded Genmab A/S from a neutral rating to an overweight rating and set a $23.00 price target on the stock in a report on Thursday, September 12th. Finally, Guggenheim started coverage on shares of Genmab A/S in a research report on Monday, August 12th. They set a buy rating on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $23.67.
GMAB stock opened at $23.80 on Tuesday. Genmab A/S has a 1 year low of $14.48 and a 1 year high of $24.50. The company has a quick ratio of 18.72, a current ratio of 18.72 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $3.01 billion and a price-to-earnings ratio of 6.33. The firm has a 50 day moving average of $22.06.
Genmab A/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: How to invest in blue-chip stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.